Johnson & Johnson (NYSE:JNJ) Shares Purchased by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. lifted its position in Johnson & Johnson (NYSE:JNJ) by 16.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,877 shares of the company’s stock after purchasing an additional 8,874 shares during the period. Johnson & Johnson comprises about 0.5% of First Trust Direct Indexing L.P.’s portfolio, making the stock its 22nd biggest holding. First Trust Direct Indexing L.P.’s holdings in Johnson & Johnson were worth $10,190,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Twin Peaks Wealth Advisors LLC acquired a new position in Johnson & Johnson during the third quarter worth $286,000. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth $31,000. Creekmur Asset Management LLC raised its position in Johnson & Johnson by 37.0% during the third quarter. Creekmur Asset Management LLC now owns 9,428 shares of the company’s stock worth $1,528,000 after acquiring an additional 2,545 shares during the period. Trajan Wealth LLC grew its holdings in shares of Johnson & Johnson by 11.3% during the third quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock worth $5,347,000 after buying an additional 3,341 shares in the last quarter. Finally, Avitas Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Avitas Wealth Management LLC now owns 29,999 shares of the company’s stock worth $4,862,000 after buying an additional 371 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.5 %

JNJ opened at $159.86 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $384.88 billion, a P/E ratio of 23.13, a P/E/G ratio of 2.90 and a beta of 0.52. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The business has a fifty day simple moving average of $163.39 and a 200-day simple moving average of $155.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.66 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.10%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, TD Securities dropped their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.